CN113748127B - 使用cd8改造的t细胞疗法治疗癌症的组合物和方法 - Google Patents

使用cd8改造的t细胞疗法治疗癌症的组合物和方法 Download PDF

Info

Publication number
CN113748127B
CN113748127B CN202080032593.3A CN202080032593A CN113748127B CN 113748127 B CN113748127 B CN 113748127B CN 202080032593 A CN202080032593 A CN 202080032593A CN 113748127 B CN113748127 B CN 113748127B
Authority
CN
China
Prior art keywords
cell
sequence
cells
seq
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080032593.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113748127A (zh
Inventor
芭芭拉·森尼诺
凯尔·雅各比
斯蒂芬妮·曼德尔-卡什曼
迈克尔·M·杜布勒伊
约翰·加农
亚历克斯·弗兰祖索夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parkert Pharmaceutical Co
Original Assignee
Parkert Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parkert Pharmaceutical Co filed Critical Parkert Pharmaceutical Co
Publication of CN113748127A publication Critical patent/CN113748127A/zh
Application granted granted Critical
Publication of CN113748127B publication Critical patent/CN113748127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN202080032593.3A 2019-05-01 2020-04-30 使用cd8改造的t细胞疗法治疗癌症的组合物和方法 Active CN113748127B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962841748P 2019-05-01 2019-05-01
US201962841753P 2019-05-01 2019-05-01
US62/841,753 2019-05-01
US62/841,748 2019-05-01
PCT/US2020/030818 WO2020223537A1 (en) 2019-05-01 2020-04-30 Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy

Publications (2)

Publication Number Publication Date
CN113748127A CN113748127A (zh) 2021-12-03
CN113748127B true CN113748127B (zh) 2025-01-10

Family

ID=73029470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032593.3A Active CN113748127B (zh) 2019-05-01 2020-04-30 使用cd8改造的t细胞疗法治疗癌症的组合物和方法

Country Status (11)

Country Link
US (4) US20210085720A1 (enExample)
EP (2) EP3962938A4 (enExample)
JP (2) JP7717619B2 (enExample)
KR (2) KR20220005050A (enExample)
CN (1) CN113748127B (enExample)
AU (2) AU2020264484A1 (enExample)
CA (2) CA3136740A1 (enExample)
IL (2) IL287643A (enExample)
MX (2) MX2021013218A (enExample)
SG (2) SG11202111865UA (enExample)
WO (3) WO2020223537A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166226B (zh) * 2018-09-28 2025-06-27 纪念斯隆-凯特琳癌症中心 表达显性负性fas的免疫应答细胞及其用途
KR20220051401A (ko) * 2019-09-06 2022-04-26 크리스퍼 테라퓨틱스 아게 배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포
WO2021216993A1 (en) * 2020-04-24 2021-10-28 Pact Pharma, Inc. Methods of determining gene editing efficiencies in cells
WO2022109277A1 (en) * 2020-11-20 2022-05-27 Pact Pharma, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY
WO2022132836A2 (en) * 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
WO2022140361A1 (en) * 2020-12-22 2022-06-30 Ludwig Institute For Cancer Research Ltd Genetically engineered lymphocytes for adoptive cell therapy
WO2022177970A1 (en) * 2021-02-18 2022-08-25 University Of Florida Research Foundation, Incorporated Enhancing metabolic fitness of t cells to treat cancer
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
EP4298230A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Codon-optimized nucleotide sequences encoding an ap-1 transcription factor
WO2022242644A1 (zh) * 2021-05-18 2022-11-24 赛斯尔擎生物技术（上海）有限公司 修饰细胞的方法
EP4352508A1 (en) * 2021-06-11 2024-04-17 Adoc Ssf, Llc Method of assessing cell products
EP4405464A4 (en) * 2021-09-21 2025-12-03 Univ Chicago METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR CANCER TREATMENT
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
IL312201A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing c-jun
CN114373511B (zh) * 2022-03-15 2022-08-30 南方医科大学南方医院 基于5hmC分子标志物检测的肠癌模型及肠癌模型构建方法
WO2023212507A1 (en) * 2022-04-26 2023-11-02 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024026490A1 (en) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Polynucleotides encoding linked antigens and uses thereof
CN120112636A (zh) * 2022-09-19 2025-06-06 埃门多生物公司 Faslg双等位基因敲除
JP2025529540A (ja) * 2022-09-19 2025-09-04 エメンドバイオ・インコーポレイテッド Ｔｅｔ２の両アレルノックアウト
US20260091113A1 (en) * 2022-09-19 2026-04-02 Emendobio Inc. Biallelic Knockout of CTLA4
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN116179495B (zh) * 2022-11-28 2025-06-06 上海恩凯细胞技术有限公司 转基因免疫细胞及其应用
CN121752591A (zh) 2023-07-03 2026-03-27 新免疫技术有限公司 异源二聚体Fc分子及其用途
AU2024316049A1 (en) * 2023-07-31 2026-02-12 T-Knife Gmbh An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
AU2024332117A1 (en) * 2023-08-25 2026-02-12 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018058002A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
WO2018170338A2 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US20020127594A1 (en) * 2000-06-22 2002-09-12 Gearing David P. Don-1 gene and polypeptides and uses therefor
US6355412B1 (en) * 1999-07-09 2002-03-12 The European Molecular Biology Laboratory Methods and compositions for directed cloning and subcloning using homologous recombination
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US8119772B2 (en) * 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
MX373687B (es) * 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
US10975137B2 (en) * 2014-11-06 2021-04-13 University Of Maryland, Baltimore CD8a and t cell receptor variants and methods of using same in modulating immune cell responses
EP4248744A3 (en) * 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
CA2996887A1 (en) * 2015-09-11 2017-03-16 Agenus Inc. Engineered host cells and methods of use thereof
AU2016323985B2 (en) * 2015-09-17 2022-12-15 Novartis Ag CAR T cell therapies with enhanced efficacy
BR112018012235A2 (pt) * 2015-12-18 2018-12-04 Sangamo Therapeutics Inc rompimento alvejado do receptor de células de mhc
EP3440101B1 (en) * 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN110831619A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 具有增强功效的生物标志和car t细胞疗法
WO2018175636A2 (en) * 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
US11512287B2 (en) * 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
WO2019004831A1 (en) * 2017-06-30 2019-01-03 Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) TREATMENT OF HEMATOLOGICAL MALIGNANCIES
AU2018329741B2 (en) * 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
SG11202004026QA (en) * 2017-10-30 2020-05-28 Pact Pharma Inc Primary cell gene editing
WO2019136335A1 (en) * 2018-01-05 2019-07-11 Gencyte Therapeutics, Inc. Precision molecular adaptor system for car-t immunotherapy
IL277722B2 (en) 2018-04-02 2025-12-01 Pact Pharma Inc Peptide-mhc compacts
WO2020049496A1 (en) * 2018-09-05 2020-03-12 Glaxosmithkline Intellectual Property Development Limited T cell modification
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
IL285534B2 (en) 2019-02-12 2025-04-01 Pact Pharma Inc Preparations and methods for identifying antigen-specific T cells
WO2020243134A1 (en) * 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018058002A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
WO2018170338A2 (en) * 2017-03-15 2018-09-20 Fred Hutchinson Cancer Research Center High affinity mage-a1-specific tcrs and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Coreceptor Scanning by the T Cell Receptor Provides a Mechanism for T Cell Tolerance;Ondrej Stepanek et al.;Cell;第336页右栏第2段，第337页 *
Role of CD8b Domains in CD8 Coreceptor Function: Importance for MHC I Binding, Signaling, and Positive Selection of CD81 T Cells in the Thymus;Re´my Bosselut et al.;Immunity;摘要 *
The Cytoplasmic Domain of CD4 Promotes the Development of CD4 Lineage T Cells;Andrea Itano et AL.;J. Exp. Med.;摘要 *

Also Published As

Publication number Publication date
SG11202111865UA (en) 2021-11-29
SG11202111532SA (en) 2021-11-29
US20260001931A1 (en) 2026-01-01
US20210085720A1 (en) 2021-03-25
WO2020223537A1 (en) 2020-11-05
US20210085721A1 (en) 2021-03-25
JP2022531231A (ja) 2022-07-06
IL287643A (en) 2021-12-01
WO2020223537A8 (en) 2021-11-11
EP3962938A4 (en) 2023-07-05
WO2020223625A1 (en) 2020-11-05
CN113748127A (zh) 2021-12-03
US20220193139A1 (en) 2022-06-23
JP7717619B2 (ja) 2025-08-04
AU2020264484A1 (en) 2021-11-04
KR20220005050A (ko) 2022-01-12
CA3136740A1 (en) 2020-11-05
EP3962938A1 (en) 2022-03-09
IL287639A (en) 2021-12-01
AU2020266579A1 (en) 2021-11-25
US12247061B2 (en) 2025-03-11
MX2021013225A (es) 2022-01-06
JP2022530653A (ja) 2022-06-30
CA3151385A1 (en) 2020-11-05
EP3953379A1 (en) 2022-02-16
KR20220004703A (ko) 2022-01-11
MX2021013218A (es) 2021-12-10
WO2020223478A1 (en) 2020-11-05
US11304978B2 (en) 2022-04-19
EP3953379A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
CN113748127B (zh) 使用cd8改造的t细胞疗法治疗癌症的组合物和方法
US20240166743A1 (en) Enhanced chimeric antigen receptors and uses thereof
US20240066063A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPY
US20230355762A1 (en) Compositions and methods for the treatment of cancer using next generation engineered t cell therapy
JP2022552197A (ja) 自己細胞療法で免疫療法の非応答者を治療する方法
HK40065093A (en) Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy
JP2026074200A (ja) 増強されたキメラ抗原受容体およびその使用
HK40040021A (en) Enhanced chimeric antigen receptors and uses thereof
HK40040021B (zh) 增强的嵌合抗原受体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40065093

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant